– USA, CA – Mount Tam Biotechnologies, Inc. (OTCBB:MNTM), a publicly traded, emerging biotechnology firm investigating the potential for inhibiting the mTOR pathway for the treatment of auto-immune diseases such as Lupus, announced today the appointment of Brian Kennedy, Ph.D., CEO of The Buck Institute for Aging, as Chairman of its Board of Directors.
“It is fitting that Dr. Kennedy take on the role as our chairman, as we maintain a close relationship with The Buck Institute, where we have licensed our initial technology, and maintain an exclusive license for autoimmune diseases” said Timothy Powers, Ph.D., CEO of Mount Tam. “His dedication to The Buck Institute’s mission to find connections between the natural process of aging and chronic diseases, combined with his intimate understanding of the mTOR pathway, create a powerful synergy that will help drive Mount Tam forward. We look forward to both unparalleled scientific breakthroughs, and measurable business success.”
Dr. Kennedy’s world-renowned research in the biology of aging began when he was a doctoral student at MIT. Under the guidance of MIT Professor Leonard Guarente, he contributed to the first studies to show that a class of proteins called Sirtuins influence aging. Currently he studies the pathways that modulate longevity in life forms ranging from yeast to mice. A major focus of his current research is to study the mammalian target of the rapamycin (mTOR) pathway. mTOR generated excitement in the age research field when it was shown recently that the drug rapamycin can extend lifespan in mice.
“Mount Tam possesses a world-class team that is dedicated to bringing innovative solutions to millions of patients suffering with Lupus,” added Dr. Kennedy.
Dr. Kennedy, 48, earned his PhD in Biology at Massachusetts Institute of Technology, where he took part in groundbreaking studies on aging. He completed postdoctoral training at the Massachusetts General Hospital Cancer Center in Charlestown, Massachusetts. Dr. Kennedy was an associate professor in the biochemistry department at the University of Washington in Seattle when he was appointed the President and the Chief Executive Officer of the Buck Institute in 2010
Mount Tam’s first investigational drug, TAM-01, is a novel mTOR inhibitor which has been optimized for the treatment of systemic lupus erythematosus (SLE), the most common form of Lupus. Licensed from The Buck Institute for Aging, this is the first molecule utilizing the Company’s unique mechanism for mTOR inhibition, and the Company is currently investigating additional applications for its proprietary platform technology.
TAM-01 has been shown to be efficacious in pre-clinical animal models of SLE while significantly reducing or abolishing the undesirable side effects of other known mTOR inhibitors such as rapamycin. The Company is currently preparing to conduct investigational new drug (“IND”) safety studies on TAM-01, with the intention of filing an IND application with the FDA shortly.
About Mount Tam Biotechnologies, Inc.
Formed on World Lupus Day 2014, Mount Tam Biotechnologies, Inc. was established to develop, optimize and bring to market innovative medicines to better the health and well being of millions of people who have been affected by autoimmune diseases. The organization’s most advanced product focuses on the treatment of SLE.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.